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Hidetoshi Yoshitani, MD,* Masahito Tamura, MD,* Haruhiko Abe, MD,*
Kazuaki Negishi, MD,y Fen-Chiung Lin, MD,z Yutaka Otsuji, MD*
Kitakyushu, Japan; Hobart, Tasmania, Australia; and Taipei, TaiwanOBJECTIVES The hypothesis of this study was that minimal left atrial volume index (LAVImin) by
3-dimensional echocardiography (3DE) is the best predictor of future cardiovascular events.
BACKGROUND Although maximal left atrial volume index (LAVImax) by 2-dimensional echocardi-
ography (2DE) is a robust index for predicting prognosis, the prognostic value of LAVImin and the supe-
riority of measurements by 3DE over 2DE have not been determined in a large group of patients.
METHODS In protocol 1, we assessed age and sex dependency of LAVIs using 2DE and 3DE in 124
normal subjects and determined their cutoff values (mean þ 2 SD). In protocol 2, 2-dimensional (2D) and
3-dimensional (3D) LAVImax/LAVImin were measured in 556 patients with high prevalence of cardiovas-
cular disease. After excluding patients with atrial ﬁbrillation, mitral valve disease, and age <18 years, 439
subjects were followed to record major adverse cardiovascular events (MACE). Patients were divided into
2 groups by the cutoff criteria of LAVI in each method.
RESULTS In protocol 1, there was no signiﬁcant age and sex dependency for each 2D and 3D LAVI. In
protocol 2, during a mean of 2.5 years of follow-up, MACE developed in 88 patients, including 32 cardiac
deaths. Kaplan-Meier survival analyses showed that all 4 LAVI cutoff criteria had signiﬁcant predictive po-
wer of MACE. After variables were adjusted for clinical variables and left ventricular ejection fraction, all 4
methods were still independently and signiﬁcantly associated with MACE, but 3D-derived LAVImin had
the highest risk ratio. 3D LAVImin also had an incremental prognostic value over 3D LAVImax.
CONCLUSIONS LAVIs by both 2DE and 3DE are powerful predictors of future cardiac events. 3D
LAVImin tended to have a stronger and additive prognostic value than 3D LAVImax. (J Am Coll Cardiol
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RA B B R E V I A T I O N S
A N D A C R O N YM S
2D = 2-dimensional
3D = 3-dimensional
2DE = 2-dimensional
echocardiography
3DE = 3-dimensional
echocardiography
CKD = chronic kidney dise
HF = heart failure
ICC = intraclass correlation
coefﬁcient
LA = left atrial
LAV = left atrial volume
LAVI = left atrial volume in
LAVImax = maximal left a
volume index
LAVImin = minimal left at
volume index
LAVmax = maximal left
atrial volume
LAVmin = minimal left
atrial volume
LV = left ventricular
LVEF = left ventricular
ejection fraction
MACE = major adverse
cardiac events
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1026emodeling of the left atrium caused by pres-
sure and/or volume overload reﬂects severity
and chronicity of underlying pathologic
conditions rather than instantaneous left
ventricular (LV) diastolic dysfunction and ﬁlling
pressure (1–3). Thus, the degree and extent of left
atrial (LA) dilation are closely coupled with disease
severity. Several previous studies demonstrated that
left atrial volume (LAV) measured by 2-dimensional
echocardiography (2DE) is a robust index for pre-
dicting future cardiovascular events in various clinical
scenarios (4–7). Although normal range and cutoffase
dex
trial
rialvalues of LAV using 2DE have been
described in guidelines, the values estab-
lished only maximal LAV and maximal
LAV corrected to body surface area
(maximal left atrial volume index [LAV-
Imax]) (2). Recently,many researchers have
focused on the importance of minimal
LAV because its size is determined by the
direct exposure of LV diastolic pressure and
reﬂects more reliably underlying pathology
(8). Biplane 2DE determination of LAV
is convenient and currently the standard
method of choice (9). However, it is
sometimes inaccurate due to the complexity
of LA shape and the inability to obtain
optimal cutting planes (10).
Transthoracic 3-dimensional echocar-
diography (3DE) has the potential for
more accurate determination of LAV
because it does not rely on geometric as-
sumptions (11,12). However, few studies
investigated the prognostic utility of LAV
measurement by 3DE (13). We hypothe-
sized that minimal left atrial volume index
(LAVImin) measured by 3DE is the best
index for predicting future cardiovascular
events.
Accordingly, the aims of this study were
to establish a normal range of LAVImax
and LAVImin and their cutoff values (mean þ 2
SD) in normal controls using 2DE and 3DE and to
evaluate the utility of these cutoff criteria to predict
future major cardiovascular events (MACE) and
cardiac death in a larger number of patients.
METHODS
Study subjects. In protocol 1, 124 healthy subjects
>18 years of age (mean age 44  16 years; range 18
to 85 years; 56 men) were enrolled as a normal
control group. They were recruited from hospital
employees and their relatives and volunteers throughadvertising. In protocol 2, a total of 556 patients
who underwent both clinically indicated 2DE and
3DE for underlying cardiac diseases were randomly
selected from our 3DE database. Exclusion criteria
included atrial ﬁbrillation, mitral valve disease, and
age <18 years. Clinical characteristics including
hypertension, diabetes mellitus, hyperlipidemia,
smoking, chronic kidney disease (CKD) and coro-
nary artery disease were evaluated for all patients
based on established criteria. CKD was deﬁned as an
estimated glomerular ﬁltration rate <60 ml/min/
1.73 m2. The study was approved by the ethics
committee of the University of Occupational and
Environmental Health Hospital, and written
informed consent was obtained from all subjects at
the time of echocardiographic examinations.
2D echocardiography. 2DE was performed using a
commercially available ultrasound machine and
transducer (iE33 and S4/S5-1 transducer, Philips
Medical Systems, Andover, Massachusetts). Three
consecutive beats in the apical 4- and 2-chamber
views including the entire left atrium were ac-
quired, with speciﬁc attention directed at ensuring
that the long axis of the left atrium was maximally
delineated and the difference between long-axis
diameter from the 2 imaging planes was <5 mm.
LAVs were determined using the biplane Simpson
method at end-systolic frames just before mitral
valve opening (maximal left atrial volume [LAV-
max]) and at end-diastolic frames coincided with
the R-wave on the electrocardiogram (minimal left
atrial volume [LAVmin]). In each view, the LA wall
was traced, excluding the LA appendage and pul-
monary veins. LAV was calculated using the
following formula on the Xcelera workstation
(Philips Medical Systems):
LAV ðmLÞ ¼ p
4
X20
i¼1Ai  Bi 
L
20
where A and B are the diameters of transverse axis
perpendicular to the long axis of the left atrium from
the apical 4- and 2-chamber views, and L is the long-
axis diameter. Values were then indexed to the body
surface area (LAVImax and LAVImin).
3D echocardiography. A fully sampled matrix-array
transducer (X3-1 or X5-1) (Philips Medical Sys-
tems) was used to acquire the 3-dimensional (3D)
full-volume datasets from apical approach during
held respiration. To ensure inclusion of the entire
LAV within the pyramidal scan volume with a
relatively higher volume rate, the datasets were ac-
quired using multibeat acquisition, wherein 4
wedge-shaped subvolumes (93  21) were ac-
quired during a single 5-s to 7-s breath hold. A 3D
Table 1. Echocardiographic Determination of LAV in Normal Subjects (n [ 124)
Total* Cutoffy Male* Female* p Value
2D LAVImax, ml/m2 24.1  6.0 36 24.9  6.5 23.4  5.4 0.1898
2D LAVImin, ml/m2 11.8  3.3 18 12.3  3.7 11.2  2.7 0.0746
3D LAVImax, ml/m2 23.4  5.0 33 24.3  4.7 22.6  5.2 0.0532
3D LAVImin, ml/m2 12.5  2.9 18 12.5  2.9 12.1  2.8 0.0766
*Values are mean  SD. yValues are mean þ 2 SD.
2D ¼ 2-dimensional; 3D ¼ 3-dimensional; LAV ¼ left atrial volume; LAVImax ¼ maximal left atrial volume index; LAVImin ¼ minimal left atrial volume index.
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1027volumetric assessment of LAV was performed using
commercially available quantitative software (3DQ
Adv, QLAB, version 9.0, Philips Medical Systems).
From the full-volume datasets, 2 orthogonal long-
axis and 1 short-axis views of the left atrium at
end-systole were selected. Manual adjustment was
required to ensure that the long axis of the left
atrium was maximally delineated in both long-
axis views. Then, 5-point marking, including the
septal, lateral, anterior, and inferior corners of the
mitral annulus and the roof of the LA wall, were
performed. The software automatically determined
the LA wall in 3D space using the deformable shell
model and made time domain LAV curve, from
which LAVmax and LAVmin were determined.
Manual adjustment of the LA wall border was
performed by cropping the 3D datasets when
inadequate tracking of the LA wall was observed.
Follow-up. Follow up information was obtained
regularly in the outpatient clinic. Telephone contact
of patients, physicians, and next of kin was per-
formed if the patient had been treated in the other
hospital. The primary endpoint was cardiac death.
The secondary endpoint was MACE including
cardiac death, nonfatal myocardial infarction,
stroke, and admission due to heart failure (HF).
Reproducibility. Intraobserver variability was deter-
mined by having the observer repeat the LAV
measurement from the same dataset 1 month apart
using 2-dimensional (2D) and 3D echocardio-
graphic images in 25 randomly selected patients.
Interobserver variability was determined by having a
second observer perform these measurements in the
same 25 patients.
Statistical analysis. Continuous data are expressed as
mean  SD. Categorical data are presented as a
number or percentage. All statistical analyses were
carried out using commercial software (JMP, version
9.0, SAS Institute Inc., Cary, North Carolina; SPSS,
version 17, SPSS Inc., Chicago, Illinois). Categorical
variables were compared using the Fisher exact test
or chi-square test whenever appropriate. A Student t
test was used to test the differences in continuousvariables between 2 groups. Linear regression anal-
ysis was used to study the relationship between 2
parameters. Bland-Altman analysis was performed
to determine bias and limits of agreement between 2
measurements. Kaplan-Meier survival analysis was
used to plot cardiac death and MACE. Differences
between survival curves were obtained by the log-
rank test. For multivariate analysis on cardiac death
and MACE, a separate Cox proportional hazard
model was used. To evaluate the inﬂuence of 2D
LAVImax, 2D LAVImin, 3D LAVImax, and 3D
LAVImin in addition to clinical variables and left
ventricular ejection fraction (LVEF), 4 models were
constructed. Incremental value of LAVI was also
assessed in 4 modeling steps using nested regression
model. The ﬁrst step consisted of ﬁtting a multi-
variate Model 0 of age, sex, hypertension, diabetes
mellitus, CKD, and coronary artery disease. Then,
LVEF was included in the second step. Next,
LAVImax was included in the third step. Finally,
LAVImin was included in the fourth step. The
change in overall log-likelihood ratio chi-square was
used to assess the increase in predictive power after
the addition of LAVI. Harrell’s C of the each model
was used as an analogous overall measure of
discrimination for predicting survival time (14). A p
value <0.05 was considered signiﬁcant. Intra-
observer and interobserver variability was calculated
as the absolute differences between the correspond-
ing 2 measurements in the percentage of their mean.
Interobserver and intraobserver reproducibility was
determined by intraclass correlation coefﬁcient
(ICC).
RESULTS
Protocol 1. No signiﬁcant age and sex dependency
of LAVImax and LAVImin by both 2DE and
3DE were observed. Although there was no sig-
niﬁcant difference between 2D LAVImax and 3D
LAVImax (p ¼ 0.3609), 3D LAVImin was
signiﬁcantly larger compared with 2D LAVImin
(p ¼ 0.0005). Cutoff values in individual methods
DC
BA
Figure 1. Comparisons of Left Atrial Volumes Between 2D and 3D Echocardiography
Linear correlation (A, B) and Bland-Altman analysis (C, D) of left atrial volume index measurements between 3-dimensional volumetric
method and 2-dimensional biplane Simpson method. 2D ¼ 2-dimensional; 3D ¼ 3-dimensional; LAVImax ¼ maximal left atrial volume index;
LAVmin ¼ minimal left atrial volume index.
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signiﬁcant but moderate correlation of LAVIs was
noted between 2DE and 3DE (Fig. 1) (LAVImax:
r ¼ 0.67, p <0.0001, LAVImin: r ¼ 0.51,
p <0.0001).
Protocol 2. A total of 117 patients were excluded
due to the presence of atrial ﬁbrillation (n ¼ 85),
mitral valve disease (n¼ 38) and age<18 years (n¼ 4).
Thus, the ﬁnal group consisted of 439 patients.
Baseline clinical characteristics and echocardio-
graphic parameters of study patients are shown in
Tables 2 and 3. 2D measurements of both LAV-
Imax and LAVImin were possible in all patients,
and 3D measurements of LAVIs were possible in all
but 1 patient. The mean volume rate of 3DE was 18
 2/s (range 14 to 23). All patients had been fol-
lowed for a median of 916 days (maximum 1,815
days). Eighty-eight patients experienced MACE,
including 32 cardiac deaths, 3 nonfatal myocardial
infarctions, 35 HF admissions, and 18 strokes.
Using their own cutoff values, patients were divided
into normal or abnormal groups in each method of
2D LAVImax, 2D LAVImin, 3D LAVImax, and
3D LAVImin measurement. Regarding cardiac
death, 2D LAVImax, 2D LAVImin, and 3DLAVImin showed a statistically signiﬁcant differ-
ence of survival rate between the normal group and
abnormal group. However, 3D LAVImax failed to
show a signiﬁcant difference in cardiac death be-
tween the 2 groups (Fig. 2). For MACE, all 4
methods showed a signiﬁcant difference in survival
curve between the normal and abnormal groups
(Fig. 3).
After adjusting for age, sex, hypertension, dia-
betes mellitus, CKD, coronary artery disease, and
LVEF, the independent associations of outcome
were analyzed using a multivariate Cox proportional
hazards model (Table 4). To avoid problems due to
collinearity, LAVmax and LAVmin parameters
were evaluated in separate models. All 4 LAVI
parameters did not provide any signiﬁcant statistical
difference for future cardiac death. However, for
MACE, all 4 LAVIs remained at statistically sig-
niﬁcant power, with 3D LAVImin having the
lowest p value (p ¼ 0.0002) and highest hazard ratio
(3.00) compared with the other 3 LAVIs.
Figure 4 shows nested regression model and
Harrell’s C-statistic. For cardiac death, the addition
of LAVImax and LAVImin by both 2DE and 3DE
had no incremental value over Model 0 þ LVEF
Table 2. Clinical Characteristics in Study Subjects (N [ 439)
Age, yrs 67  14 (18–97)
Men 251 (57)
Body surface area, m2 1.53  0.19 (1.03–2.31)
Heart rate, beats/min 67  13 (41–119)
Blood pressure, mm Hg
Systolic 143  28 (74–256)
Diastolic 77  16 (40–137)
Medical history
Hypertension 305 (70)
Diabetes mellitus 152 (35)
Hyperlipidemia 134 (31)
Smoking 88 (26)
Medical diagnosis
Coronary artery disease 132 (30)
Previous myocardial infarction 30 (7)
Hypertensive heart disease 70 (16)
Aortic valve disease (moderate or
severe)
73 (17)
Dilated cardiomyopathy 25 (6)
Secondary cardiomyopathy 19 (4)
Hypertrophic cardiomyopathy 16 (4)
Laboratory tests
Glycosylated hemoglobin, % 6.1  1.3 (4.0–12.6)
Low–density lipoprotein, mg/dl 109  36 (22–289)
Triglyceride, mg/dl 115  68 (26–623)
eGFR, ml/min 55  36 (3–199)
Medications
ACEi or ARB 133 (31)
Aspirin 157 (37)
Beta-blocker 135 (31)
Calcium channel blocker 179 (42)
Diuretic 133 (31)
Warfarin 41 (10)
Values are mean  SD (range) or n (%).
ACEi ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin
receptor blocker; eGFR ¼ estimated glomerular ﬁltration rate.
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1029(Figs. 4A and 4B). For MACE, although the addi-
tion of both 2D and 3D LAVImax showed signiﬁ-
cance for incremental value in addition to Model
0 þ LVEF, only 3D LAVImin offered additional
signiﬁcant incremental value (Figs. 4C and 4D).
To determine the effect of HF and CKD on
prognostic value of LAVIs, Kaplan-Meier analysis
was performed in subgroups with and without HF
or CKD (Table 5). None of the LAVI cutoff criteria
showed a signiﬁcant difference in survival for cardiac
death and MACE in patients with HF. Although
2D LAVImax showed signiﬁcance for predictingcardiac death in patients without HF, all 4 LAVI
cutoff values discriminated signiﬁcantly MACE
rates in patients without HF. All cutoff values
showed signiﬁcant prognostic power for MACE in
patients with CKD. In addition, 2D LAVImax,
2D LAVImin, and 3D LAVImin have predictive
value for cardiac death in patients without CKD.
Observer variabilities. The intraobserver variabi-
lity for the measurements was 2D LAVmax
(5.4  4.2%), 3D LAVmax (5.1  3.9%), 2D
LAVmin (8.4  7.3%), 3D LAVmin (9.4  8.2%).
The corresponding interobserver variability was 2D
LAVmax (11.0  11.5%); 3D LAVmax
(6.2  4.0%), 2D LAVmin (15.1  17.1%), 3D
LAVmin (9.8  11.6%), respectively. The intra-
observer ICC for 2D LAVmax, 3D LAVmax, 2D
LAVmin, and 3D LAVmin were 0993, 0.998,
0.995, and 0.996, respectively. The interobserver
ICC for 2D LAVmax, 3D LAVmax, 2D LAVmin,
and 3D LAVmin were 0.987, 0.995, 0.990, and
0.996, respectively.
D I SCUSS ION
There were 3 major ﬁndings in this study. 1) 2D
LAVImax, 2D LAVImin, and 3D LAVImin were
powerful predictors of future cardiac death and all 4
methods were robust index for predicting future
MACE. 2) After adjusting for age, sex, hyperten-
sion, diabetes mellitus, CKD, coronary artery dis-
ease, and LVEF, all 4 methods were independently
associated with MACE but not cardiac death.
3) 2D LAVImin failed to show signiﬁcant incre-
mental value in addition to 2D LAVImax for
predicting MACE, whereas 3D LAVImin showed
signiﬁcant incremental value in addition to 3D
LAVImax for predicting MACE.
Previous studies. Assessment of LA size has
evolved from 1-dimensional M-mode for LA
diameter (15), 2D biplane area-length, or Simpson
method for LA volume to 3D semiautomatic atrial
border tracing for LA volume with increasing ac-
curacy and reproducibility (12,16). Insights from
cardiac computed tomography and anatomic studies
showed that the left atrium has a complex shape
with an irregular ellipsoid LA free wall and oblique
planar interatrial septal wall (17,18). Pitfalls exist in
2DE determination of LAV because: 1) the LA and
LV long axes do not appear in the same cutting
plane; 2) it is not always guaranteed that apical
4- and apical 2-chamber views are exactly 90
perpendicular to each other; and 3) the 2D cutting
plane obtained often does not bisect the center of
the LA short-axis view (10). For these reasons,
Table 3. Echocardiographic Findings of Study Patients
(N [ 439)
2D echocardiography
2D LAVImax, ml/m2 41  16 (12–105)
2D LAVImin, ml/m2 25  13 (5–90)
3D echocardiography
3D LVEDVI, ml/m2 57  27 (15–203)
3D LVESVI, ml/m2 28  22 (4–166)
3D LVEF, % 55  15 (13–86)
3D LAVImax, ml/m2 41  16 (12–100)
3D LAVImin, ml/m2 25  13 (5–83)
E, cm/s 77  26 (25–162)
A, cm/s 85  33 (26–206)
E/A 1.03  0.61 (0.27–4.10)
Deceleration time, ms 231  78 (63–577)
E0 average, cm/s 5.7  2.3 (2.0–16.0)
E/E0 average 15.0  7.0 (4.6–51.0)
Values are mean  SD (range).
A ¼ peak mitral ﬂow velocity at atrial contraction; E ¼ peak mitral ﬂow
velocity of the early rapid ﬁlling; E/A ¼ ratio of E velocity to A velocity;
e0 ¼ early diastolic velocity of the mitral annulus; E/e0 ¼ ratio of E velocity to
e0 ; LVEDVI ¼ left ventricular end-diastolic volume index; LVEF ¼ left ventric-
ular ejection fraction; LVESV ¼ left ventricular end-systolic volume index;
other abbreviations as in Table 1.
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1030observer variabilities of LAV by 2DE measurements
were reported to be larger than those by 3DEA
C
Figure 2. Kaplan-Meier Survival Analysis for Cardiac Death
Cumulative percentage survival by cardiac death during follow-up of 2-d
atrial volume (B), 3-dimensional maximal left atrial volume (C), and 3-di
2 groups according to mean þ 2 SD cutoff values derived from healthmeasurements (10,11,19). Compared with multi-
detector computed tomography as standard refer-
ence, a previous study revealed that there was 19%
underestimation of LAV by 2DE but only 8% un-
derestimation by 3DE (11). Similarly, compared
with cardiac magnetic resonance as standard refer-
ence, there were 31-ml and 16-ml underestimations
of LAVmax and LAVmin by 2DE but only 1-ml
underestimation and 0-ml difference by 3D LAV-
max and LAVmin (12).
Recommendation for determining LA size was
focused on the maximal volume measurement
(1,2,6). LAVImax has been shown to be a potent
biomarker for ﬁrst-ever ischemic stroke (20).
LAVImax provided independent information over
clinical and other echocardiographic variables for
predicting mortality in patients with HF (21). In
another large sample study of 36,561 patients with
preserved LVEF for an average follow-up of 1.7 
1.0 years, LAVImax predicted mortality risk irre-
spective of LV geometry (22).
In recent investigations, researchers found the
LAVImin correlated more with cardiovascular
events and was predictive of outcomes. LAVmin but
not LAVmax was found to be a signiﬁcant predictor
of the ﬁrst atrial ﬁbrillation or ﬂutter after being
entered in a multivariate model adjusted forB
D
imensional maximal left atrial volume (A), 2-dimensional minimal left
mensional minimal left atrial volume (D). Patients were stratiﬁed into
y subjects.
BA
DC
Figure 3. Kaplan-Meier Survival Analysis for MACE
Cumulative percentage survival free from major adverse cardiovascular events of 2-dimensional maximal left atrial volume (A), 2-dimensional
minimal left atrial volume (B), 3-dimensional maximal left atrial volume (C), and 3-dimensional minimal left atrial volume (D).
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1031covariates (23). Another study also showed that
LAVmin measured by 3DE was the best indepen-
dent predictor of adverse cardiovascular events
among 2DE- and 3DE-derived LV and LA pa-
rameters (13). To investigate the prevalence, risk
factors, and possible cardiac predictors of silent
brain infarcts in the community, an epidemiological
study showed that LAVmin was identiﬁed as a
better correlate of LV diastolic function than
LAVmax (8), and LAVImin and LA total emptying
fraction were more strongly associated with sub-
clinical brain infarction and white matter hyper-
intensity volume than LAVImax (24). Although
both LAVmax and LAVmin increased gradually
with progression of LV diastolic function, the in-
crease in LAVmin with worsening diastolic function
was more pronounced and showed an increase in
even mild diastolic dysfunction, whereas LAVmax
increased in later stages of diastolic dysfunction (8).
Current study. This study was unique because we
ﬁrst established cutoff values of 2D and 3D LAV-
Imax/LAVImin for healthy subjects, and then we
determined the utility of each criterion for the
prediction of prognosis of both cardiac death and
MACE in a large patient group. Kaplan-Meier
analysis revealed that 2D LAVImax/min and 3D
LAVImin had signiﬁcant power to predict cardiacdeath. However, we could not demonstrate the
signiﬁcance in 3D LAVImax, possibly due to the
small number of cardiac deaths (n ¼ 32). On the
other hand, all 4 methods showed signiﬁcant power
to predict future MACE, with 3D LAVImin being
the best due to the highest chi-square value. This is
in agreement with previous studies that showed that
LAVImin is more reﬂective of chronic LV diastolic
pressure/volume overload and is a better predictor of
cardiac events than LAVImax (8,25).
Using multivariate Cox proportional hazards
model adjusted for age, sex, major cardiovascular
risk factors, and LVEF, none of LAVI cutoff
criteria showed prognostic utility for future cardiac
death, which again may be due to the small number
of cardiac deaths that occurred in our study group.
On the other hand, all 4 methods of LAVI de-
terminations showed a robust predictive power for
future MACE, with 3D LAVImin having the
most signiﬁcant p value and highest hazard ratio
among all.
We found that 3D LAVImin, but not 2D
LAVImin, had incremental predictive value for
future MACE over the model that already included
age, sex, major clinical risk factors, LVEF, and
LAVImax. Incremental value of 3DE reinforced
the superiority of 3DE over 2DE, as reported in
Table 4. Predictors of Cardiac Death and Major Adverse Cardiac Events
Cardiac Death
Univariate Analysis
Multivariate Analysis
Model 1 Model 2 Model 3 Model 4
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
Age 1.05 (1.02–1.08) 0.0014 1.05 (1.01–1.08) 0.0041 1.04 (1.01–1.08) 0.0062 1.04 (1.01–1.08) 0.0076 1.04 (1.01–1.08) 0.0101
Sex 1.07 (0.53–2.22) 0.8473 0.94 (0.43–2.09) 0.8711 0.96 (0.44–2.13) 0.9094 0.87 (0.39–1.98) 0.7417 0.94 (0.42–2.14) 0.8849
HT 0.94 (0.46–2.08) 0.8767 0.44 (0.20–1.03) 0.0592 0.44 (0.20–1.03) 0.0570 0.48 (0.22–1.12) 0.0890 0.45 (0.20–1.04) 0.0621
DM 1.42 (0.69–2.86) 0.3338 1.32 (0.61–2.79) 0.4745 1.33 (0.61–2.79) 0.4641 1.44 (0.66–3.10) 0.3463 1.40 (0.64–2.99) 0.3886
CKD 4.30 (1.89–11.5) 0.0003 3.53 (1.47–9.88) 0.0039 3.44 (1.44–9.59) 0.0045 3.42 (1.43–9.57) 0.0048 3.33 (1.39–9.29) 0.0058
CAD 1.83 (0.89–3.66) 0.0976 1.30 (0.59–2.78) 0.5089 1.31 (0.60–2.80) 0.4932 1.25 (0.57–2.71) 0.5693 1.24 (0.56–2.69) 0.5917
LVEF 0.97 (0.95–0.99) 0.0042 0.98 (1.00–1.02) 0.0621 0.98 (0.95–1.00) 0.0538 0.97 (0.95–1.00) 0.0221 0.98 (0.95–1.00) 0.0447
2D LAVImax 2.97 (1.35–7.44) 0.0057 2.28 (0.98–5.94) 0.0563
2D LAVImin 3.59 (1.50–10.6) 0.0028 2.38 (0.93–7.32) 0.0710
3D LAVImax 2.08 (0.94–5.22) 0.0710 1.37 (0.58–3.61) 0.4860
3D LAVImin 3.48 (1.45–10.3) 0.0038 2.28 (0.89–7.03) 0.0897
MACE
Univariate Analysis
Multivariate Analysis
Model 1 Model 2 Model 3 Model 4
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
Age 1.02 (1.01–1.04) 0.0055 1.02 (1.00–1.04) 0.0303 1.02 (1.00–1.04) 0.0533 1.02 (1.00–1.04) 0.0432 1.02 (1.00–1.04) 0.0593
Sex 1.29 (0.84–2.01) 0.2464 1.06 (0.66–1.73) 0.8141 1.09 (0.68–1.78) 0.7145 1.10 (0.68–1.81) 0.6928 1.14 (0.71–1.87) 0.5841
HT 1.75 (1.06–3.03) 0.0273 0.93 (0.54–1.66) 0.7933 0.93 (0.55–1.67) 0.8118 0.99 (0.58–1.75) 0.9597 0.93 (0.55–1.66) 0.8075
DM 1.88 (1.23–2.87) 0.0039 1.60 (1.01–2.51) 0.0453 1.62 (1.03–2.54) 0.0363 1.62 (1.03–2.56) 0.0388 1.64 (1.04–2.57) 0.0335
CKD 3.26 (2.02–5.46) <0.0001 2.50 (1.50–4.31) 0.0003 2.39 (1.44–4.11) 0.0006 2.43 (1.46–4.18) 0.0005 2.34 (1.42–4.03) 0.0007
CAD 1.73 (1.12–2.64) 0.0136 1.00 (0.62–1.60) 0.9901 0.99 (0.62–1.57) 0.9643 1.00 (0.62–1.61) 0.9860 0.97 (0.60–1.54) 0.8882
LVEF 0.97 (0.96–0.99) <0.0001 0.98 (0.97–1.00) 0.0152 0.98 (0.97–1.00) 0.0147 0.98 (0.97–1.00) 0.0145 0.98 (0.97–1.00) 0.0290
2D LAVImax 2.71 (1.69–4.49) <0.0001 2.19 (1.31–3.82) 0.0025
2D LAVImin 3.64 (2.14–6.60) <0.0001 2.38 (1.35–4.45) 0.0022
3D LAVImax 3.19 (1.88–5.78) <0.0001 2.24 (1.28–4.17) 0.0041
3D LAVImin 4.31 (2.47–8.15) <0.0001 3.00 (1.66–5.81) 0.0002
CAD ¼ coronary artery disease; CI ¼ conﬁdence interval; CKD ¼ chronic kidney disease; DM ¼ diabetes mellitus; HR ¼ hazard ratio; HT ¼ hypertension; other abbreviations as in Tables 1 and 3.
W
u
et
al.
J
A
C
C
:
C
A
R
D
IO
V
A
S
C
U
L
A
R
IM
A
G
IN
G
,
V
O
L
.
6
,
N
O
.
1
0
,
2
0
1
3
Prognostic
Value
of
3D
LA
VI
O
C
T
O
B
E
R
2
0
1
3
:1
0
2
5
–
3
5
1032
BA
DC
Figure 4. Incremental Values of Left Atrial Volumes for Predicting Future Cardiovascular Events
Nested regression models for cardiac death by 2D echocardiography (A) and 3D echocardiography (B) and major adverse cardiovascular
events by 2D echocardiography (C) and 3D echocardiography (D). Level I consisted of multivariate Model 0 including age, sex, hypertension,
diabetes mellitus, chronic kidney disease, and coronary artery disease. Level II consisted of the addition of left ventricular ejection fraction
(LVEF) on Model 0. Level III consisted of the addition of maximal left atrial volume (LAVImax) on Model 0 and LVEF. Level IV consisted of
adding minimal left atrial volume (LAVImin) on Model 0, LVEF, and LAVImax. *Statistically signiﬁcant. 2D ¼ 2-dimensional; 3D ¼ 3-dimensional.
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1033recently published studies (8,13,24), for the prog-
nosis of MACE.
A signiﬁcant predictive value of LAVI for cardiac
death and MACE could not be demonstrated in
patients with HF because these patients wereTable 5. p Values Derived From Kaplan-Meier Analysis of LAVI in P
HF (D)
Cardiac Death M
2D LAVImax 0.7533 0.0
2D LAVImin 0.6555 0.2
3D LAVImax 0.5949 0.1
3D LAVImin 0.8691 0.1
CKD (D)
Cardiac Death M
2D LAVImax 0.2384 0.0
2D LAVImin 0.0730 0.0
3D LAVImax 0.4205 0.0
3D LAVImin 0.0845 0.0
*p < 0.05.
CKD ¼ chronic kidney disease; HF ¼ heart failure; MACE ¼ major adverse cardiacalready associated with increased LAV; hence, no
independent prognostic power from the established
LAVI cutoff criteria could be observed. However, in
patients without HF, all 4 LAVI cutoff values
showed signiﬁcance for predicting future MACE.atients With and Without HF/CKD
HF (L)
ACE Cardiac Death MACE
735 0.0480* 0.0452*
718 0.2862 0.0037*
630 0.3693 0.0173*
508 0.2549 0.0027*
CKD (L)
ACE Cardiac Death MACE
290* 0.0090* 0.4452
330* <0.0001* 0.1985
039* 0.1616 0.1985
026* <0.0001* 0.1985
events; other abbreviations as in Table 1.
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1034Patients with CKD are associated with a higher risk
of death and cardiovascular events (26–28). All
LAVI criteria were useful for predicting MACE in
patients with CKD, suggesting the incremental
predictive value of LAVIs in patients who are
already at high cardiovascular risk.
Clinical implications. This study supported LAV-
Imax as a powerful predictor of MACE, but even
more so to verify that LAVImin has greater sig-
niﬁcance in the prognosis of future MACE. LAV
measurements by 3DE are superior to 2DE
against the reference standard (9,10,17). We also
demonstrated that 3D LAVImin has a stronger
and additive prognostic value over 3D LAVImax.
The routine echocardiography should therefore
include assessment of LAVImin for predicting
cardiovascular events, especially in patients who
already have higher cardiovascular risk proﬁles,
determined by either 2DE or 3DE. In addition,
serial LAVI follow-up can provide a simple,
quick, yet quantiﬁable log of clinical progress and
treatment effect (29).
Study limitations. First, our study subjects are a
high-risk population with higher prevalence of
cardiovascular disease. Therefore, the results of our
study may not be appropriately extrapolated to the
general population. Second, we could not determine
statistically signiﬁcant superiority of 3D LAVI over
2D LAVI for future cardiovascular events. Due tocollinearity, it is possible that a higher power is
needed to detect differences in the prognostic value
of 2D and 3D parameters. Third, patients were
enrolled in retrospective fashion; thus, temporal
relation to speciﬁc cardiac events may at times be
difﬁcult to assess. Fourth, the study population
consisted entirely of Japanese subjects, and the
relevance of this study to other ethnic backgrounds
awaits further research. Last, only patients with
echocardiographic images that could be adequately
used for 2DE and 3DE analyses were enrolled in
the study and may result in selection bias.CONCLUS IONS
Both LAVImax and LAVImin determined by 2DE
and 3DE were highly prognostic indexes for pre-
dicting future cardiovascular events in a high-risk
population. Our study showed that 3D LAVImin
seemed to be the best predictor of future MACE.
Thus, it should be useful to establish 3D LAVImin
as the best predictor in larger, multicenter, pro-
spective study.
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